Neutralizing antibodies and cytokines in breast milk after mRNA vaccination against 2019 coronavirus infection (COVID19).
Evaluation of immune response to
mRNA-based vaccine against coronavirus disease 2019 (COVID19) present in breast
milk and transmission of immune response to breast-fed infants We enrolled 30
lactating women who received mRNAbased COVID19 vaccines from January through
April 2021 in this cohort study. Women provided serial milk samples, including
milk expressed before vaccination, across 2–3 weeks after the first dose, and
across 3 weeks after the second dose. Women provided their blood, spotted on
cards (dried blood spots), 19 days after the first dose and 21 days after the
second dose. Stool samples from the breastfed infants were collected 21 days
after mothers second vaccination. Prepandemic samples of milk, dried blood
spots, and infant stool were used as controls. Milk, dry blood stains, and baby
stools were tested for receptor-binding domain (RBD) -specific immunoglobulin
(Ig) A and IgG using enzyme immunoassays. Milk samples were tested for the
presence of neutralizing antibodies against spikes and four concerns: D614G,
alpha (B.1.1.7), beta (B.1.351), and gamma (P.1). The concentrations of 10
cytokines were measured in milk samples. Milk from women immunized with COVID
19 neutralized four mutant strains of concern, primarily spikes caused by
anti-RBD IgG. The milk's immune response also included a significant increase
in interferon gamma. Breast-fed babies reflected an immune response to maternal
vaccination. Anti-RBD IgG and anti-RBDIgA were detected in 33% and 30% of
infant stool samples, respectively. The level of anti-RBD antibody in the
baby's stool was correlated with the side effects of the maternal vaccine. Mean
anti-RBD antibody levels were below the positive limit in pre-pandemic milk and
baby stool samples. Humoral and cell-mediated immune responses to mRNA-based
COVID 19 vaccination are found in most women's milk. Milk anti-RBD antibody can
neutralize anxious variants of coronavirus 2 (SARSCoV2) spikes and severe acute
respiratory syndrome. Anti-RBD antibodies are transferred to breast-fed infants
who may give passive immunity to SARSCoV2.Two mRNA-based coronavirus disease
2019 (COVID19) vaccines, BNT162b2 (PfizerBioNTech) and mRNA1273 (Moderna) are
approved for use in the United States. Breastfeeding for clinical trials of two
mRNA vaccine candidates The woman inside was not included. The Center for
Disease Control and Prevention, the American University of Obstetrics and
Gynecology, and the Academy of Breast Nutrition Medicine recommend vaccination
of women with breast nutrition. At the time of this writing, the COVID19
vaccine has not yet been approved. For infants under the age of 5, passive
immunity given to infants breast-fed by a developing fetus through the placenta
of a vaccinated mother or a vaccinated pregnant woman is probably severe acute
respiratory syndrome. It is the only way to protect your baby from infection with
coronavirus 2 (SARSCoV2).
Comments
Post a Comment